News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2026

19 May, 2026 Egetis to present healthcare resource drivers and cost in MCT8 deficiency at ISPOR 2026 News Corporate Information Other Corporate Information English IR Optional
13 May, 2026 Exercise of options under employee stock option program and notification of insider trading News Corporate Information Other Corporate Information English IR Optional
7 May, 2026 Egetis Therapeutics to Participate in Leading International Medical Conferences in 2026 News Corporate Information Other Corporate Information English IR Optional
5 May, 2026 Egetis Announces Grant of Patent for MCT8 Deficiency Composition in the U.S. News Corporate Information Other Corporate Information English IR Optional
30 April, 2026 Egetis Therapeutics to Participate in Pediatric Endocrine Society Annual Meeting 2026 News Corporate Information Other Corporate Information English IR Optional
30 April, 2026 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional
29 April, 2026 Interim report Q1 2026 News English Regulatory MAR Report Interim Q1 IR Optional
24 April, 2026 Invitation to Presentation of Egetis’ First Quarter 2026 Report on April 29, 2026 News Corporate Information Other Corporate Information English IR Optional
21 April, 2026 Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 350 million (approximately USD 38 million) News Corporate Action Shares Issuance English Regulatory MAR IR Optional
21 April, 2026 Egetis Therapeutics announces the intention to carry out a directed share issue of approximately SEK 350 million (approximately USD 38 million) News Corporate Action Shares Issuance English Regulatory MAR IR Optional
14 April, 2026 Bulletin from Egetis Therapeutics’ Annual General Meeting 2026 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
9 April, 2026 Egetis Appoints Tiago Nunes as Chief Medical Officer News Corporate Information Staff change English IR Optional
8 April, 2026 Egetis Receives Conditional FDA Acceptance of Proprietary Name Emcitate® News Corporate Information Other Corporate Information English IR Optional
27 March, 2026 Egetis Announces FDA Acceptance and Priority Review of NDA for Emcitate® (tiratricol) for MCT8 Deficiency News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
24 March, 2026 Egetis Therapeutics’ Annual Report 2025 published News English Regulatory VPML Report Annual IR Optional
12 March, 2026 NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL) News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
9 March, 2026 Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S. News Corporate Information Other Corporate Information English IR Optional
2 March, 2026 Egetis Therapeutics Launches Educational Websites on MCT8 Deficiency for Physicians and Caregivers News Corporate Information Other Corporate Information English IR Optional
26 February, 2026 Year-End Report January-December 2025 News English Regulatory MAR Report Interim Yearend IR Optional
24 February, 2026 Egetis Therapeutics to Present at Upcoming Investor Events News Corporate Information Other Corporate Information English IR Optional
19 February, 2026 Invitation to presentation of Egetis’ fourth quarter and year-end 2025 report on February 26, 2026 News Corporate Information Other Corporate Information English IR Optional
16 February, 2026 Egetis provides update on progress with the development of Emcitate® (tiratricol) for MCT8 deficiency in Japan News Corporate Information Other Corporate Information English IR Optional
4 February, 2026 FDA's rare pediatric disease priority review program extended until 2029 News Corporate Information Other Corporate Information English IR Optional
29 January, 2026 Egetis Completes the U.S. Rolling NDA Submission for Emcitate® (tiratricol) for Treatment of MCT8 Deficiency News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
16 January, 2026 Chairman of the Board of Egetis Therapeutics acquires shares News Corporate Information Other Corporate Information English IR Optional
Next

Calendar and upcoming reports

August 21, 2026 (7:00am CEST)
Interim Report Q2 2026

November 6, 2026 (7:00am CET)
Interim Report Q3 2026

Show more events

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]